Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

growth hormone disorder

- PMLiVE

Merck licenses University of Edinburgh research tool

Gains access to novel disease progression technology

- PMLiVE

Takeda launches drug discovery biotech

Hopes Bridge Medicines will streamline the development process

- PMLiVE

EMA starts review of Pfizer and Merck’s PD-L1 inhibitor

Avelumab looks set to be the first new drug to treat Merkel cell carcinoma

- PMLiVE

Merck completes €15m Spanish biotech facility expansion

Enlarged Tres Cantos site will help meet demand for fertility and growth hormone drugs

- PMLiVE

Merck sees €2bn from new launches by 2022

Expects to deliver total sales of €4bn with multiple sclerosis, fertility and cancer drugs portfolio

Celgene building

Celgene bolsters blood cancer portfolio with $600m EngMab buy

Consolidates position as top company in current multiple myeloma market

- PMLiVE

The global scourge of counterfeit medicines

Pharmaceuticals are a prime target for organised crime

- PMLiVE

Merck KGaA appoints chief strategy officer

Isabel De Paoli will take up the role from 1 October

Shire Basingstoke

Shire gives up on Momenta-partnered Humira biosimilar

Will fund programme for another 12 months while divesting ongoing activities to Momenta

- PMLiVE

Novartis seeks first-line use for lung cancer drug Zykadia

Looks to go head-to-head with Pfizer/Merck KGaA’s Xalkori and Roche’s Alecensa

- PMLiVE

EMD Serono president James Hoyes joins consultants RxC

Takes up a role as executive partner at the US management consulting firm

- PMLiVE

Managing value: Why early asset development and commercialisation are important

Realising the full value of your asset - clinically and commercially - means thinking beyond the pure scientific value, even at the very early stages of development

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links